AU2015308735B2 - Compounds that inhibit Mcl-1 protein - Google Patents
Compounds that inhibit Mcl-1 protein Download PDFInfo
- Publication number
- AU2015308735B2 AU2015308735B2 AU2015308735A AU2015308735A AU2015308735B2 AU 2015308735 B2 AU2015308735 B2 AU 2015308735B2 AU 2015308735 A AU2015308735 A AU 2015308735A AU 2015308735 A AU2015308735 A AU 2015308735A AU 2015308735 B2 AU2015308735 B2 AU 2015308735B2
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- chloro
- naphthalene
- methyl
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 C[C@](CCCC[C@@]([C@](CC1)[C@]1CN(C1)c(cc(cc2)*(N3)=O)c2OC*1(CCCc1c2)c1ccc2Cl)O)S3(=O)=O Chemical compound C[C@](CCCC[C@@]([C@](CC1)[C@]1CN(C1)c(cc(cc2)*(N3)=O)c2OC*1(CCCc1c2)c1ccc2Cl)O)S3(=O)=O 0.000 description 11
- MYXXRSVHFZYSFI-UHFFFAOYSA-N CC(C)(CC=C)CSc1ncccn1 Chemical compound CC(C)(CC=C)CSc1ncccn1 MYXXRSVHFZYSFI-UHFFFAOYSA-N 0.000 description 1
- SVDLLEGUCRNLOM-KFSAQIHNSA-N CC(C)CC([C@H](C)C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCCc1c2)c1ccc2Cl)O)S3(=O)=O Chemical compound CC(C)CC([C@H](C)C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCCc1c2)c1ccc2Cl)O)S3(=O)=O SVDLLEGUCRNLOM-KFSAQIHNSA-N 0.000 description 1
- SVDLLEGUCRNLOM-QVXKNGAHSA-N CC(C)C[C@@H]([C@@H](C)C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCC1)c(cc2)c1cc2Cl)O)S3(=O)=O Chemical compound CC(C)C[C@@H]([C@@H](C)C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCC1)c(cc2)c1cc2Cl)O)S3(=O)=O SVDLLEGUCRNLOM-QVXKNGAHSA-N 0.000 description 1
- SDZKLXNBWNFNDP-PSSLRWOHSA-N CC(C)O[C@H]([C@H](CC1)[C@@H]1CN(CCCCc1c2)c(cc(cc3)C(N4)=O)c3OCc1ccc2Cl)/C=C/C[C@H](C)[C@@H](C)S4(=O)=O Chemical compound CC(C)O[C@H]([C@H](CC1)[C@@H]1CN(CCCCc1c2)c(cc(cc3)C(N4)=O)c3OCc1ccc2Cl)/C=C/C[C@H](C)[C@@H](C)S4(=O)=O SDZKLXNBWNFNDP-PSSLRWOHSA-N 0.000 description 1
- QAVBOZQXNPZZAO-UHNAYKLQSA-N CC(C)[C@@H]([C@H](C)C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c2cc(C(N3)=O)ccc2OCc(cc2)c1cc2Cl)O)S3(=O)=O Chemical compound CC(C)[C@@H]([C@H](C)C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c2cc(C(N3)=O)ccc2OCc(cc2)c1cc2Cl)O)S3(=O)=O QAVBOZQXNPZZAO-UHNAYKLQSA-N 0.000 description 1
- KBGUVESLYYLODF-PXACGUQISA-N CC(C)[C@H]([C@@H](C)C/C=C/[C@@H](CC1(CC1)CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)S3(=O)=O Chemical compound CC(C)[C@H]([C@@H](C)C/C=C/[C@@H](CC1(CC1)CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)S3(=O)=O KBGUVESLYYLODF-PXACGUQISA-N 0.000 description 1
- QAVBOZQXNPZZAO-QTOPTAKESA-N CC(C)[C@H]([C@@H](C)C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)S3(=O)=O Chemical compound CC(C)[C@H]([C@@H](C)C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)S3(=O)=O QAVBOZQXNPZZAO-QTOPTAKESA-N 0.000 description 1
- IPUJFMAQBHXATR-IGRSSCOASA-N CC(C)[C@H]([C@H](C)C/C=C/C(/[C@H]1C(CN(C2)c(cc(cc3)C(N)=O)c3OC[C@@]2(CCC2)c(cc3)c2cc3Cl)(C2)C2C1)=[O]\CCOC)S=O Chemical compound CC(C)[C@H]([C@H](C)C/C=C/C(/[C@H]1C(CN(C2)c(cc(cc3)C(N)=O)c3OC[C@@]2(CCC2)c(cc3)c2cc3Cl)(C2)C2C1)=[O]\CCOC)S=O IPUJFMAQBHXATR-IGRSSCOASA-N 0.000 description 1
- FQGUIFDAZPUIDZ-UHFFFAOYSA-N CC(CC=C)C(CC1CCC1)S(N)(=O)=O Chemical compound CC(CC=C)C(CC1CCC1)S(N)(=O)=O FQGUIFDAZPUIDZ-UHFFFAOYSA-N 0.000 description 1
- ZAJYCLALRDWCBZ-PAJWBNQNSA-N CC([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCC1)c(cc2)c1cc2Cl)/C=C/CCCS3(=O)=O Chemical compound CC([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCC1)c(cc2)c1cc2Cl)/C=C/CCCS3(=O)=O ZAJYCLALRDWCBZ-PAJWBNQNSA-N 0.000 description 1
- AJDCOTRGZXUEMA-UHFFFAOYSA-N CC1C2C1CCC2 Chemical compound CC1C2C1CCC2 AJDCOTRGZXUEMA-UHFFFAOYSA-N 0.000 description 1
- KAVKMWAZVAJTBS-GDNUWSCESA-N CCC/C=C/[C@@H]([C@H]1[C@H](CN(CCCC2)c(cc(cc3)C(O)=O)c3OCc(cc3)c2cc3Cl)CC1)O Chemical compound CCC/C=C/[C@@H]([C@H]1[C@H](CN(CCCC2)c(cc(cc3)C(O)=O)c3OCc(cc3)c2cc3Cl)CC1)O KAVKMWAZVAJTBS-GDNUWSCESA-N 0.000 description 1
- STYFTVRCRMUIGS-CFZLGYCLSA-N CCCCCS(NC(c(cc1)cc(N(C[C@H](CC2)[C@@H]2[C@H](C)O)C[C@H](C)CC2)c1OCc(cc1)c2cc1Cl)=O)(=O)=O Chemical compound CCCCCS(NC(c(cc1)cc(N(C[C@H](CC2)[C@@H]2[C@H](C)O)C[C@H](C)CC2)c1OCc(cc1)c2cc1Cl)=O)(=O)=O STYFTVRCRMUIGS-CFZLGYCLSA-N 0.000 description 1
- VDCRSQNBHMQFIJ-GEUANWCOSA-N CC[C@H](C(C)C/C=C/C([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)S3(=O)=O Chemical compound CC[C@H](C(C)C/C=C/C([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)S3(=O)=O VDCRSQNBHMQFIJ-GEUANWCOSA-N 0.000 description 1
- SRMFOOCOSPWHLM-KQTMHKRDSA-N COC([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)/C=C/CCCS3(=O)=O Chemical compound COC([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)/C=C/CCCS3(=O)=O SRMFOOCOSPWHLM-KQTMHKRDSA-N 0.000 description 1
- KUHCCXQLIMSSRQ-PUDQKYKZSA-N C[C@@H](C/C=C/[C@@H]([C@@H]1C(CN(C2)c(cc(cc3)C(N4)=O)c3OC[C@@]2(CCC2)c(cc3)c2cc3Cl)=CC1)OCCOCCOC)[C@@H](C)S4(=O)=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@@H]1C(CN(C2)c(cc(cc3)C(N4)=O)c3OC[C@@]2(CCC2)c(cc3)c2cc3Cl)=CC1)OCCOCCOC)[C@@H](C)S4(=O)=O KUHCCXQLIMSSRQ-PUDQKYKZSA-N 0.000 description 1
- OZUHIDVLLAIMHZ-XCJBHORUSA-N C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCC1)c(cc2)c1cc2Cl)OCCOCCOCCOC)[C@@H](C)S3(=O)=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCC1)c(cc2)c1cc2Cl)OCCOCCOCCOC)[C@@H](C)S3(=O)=O OZUHIDVLLAIMHZ-XCJBHORUSA-N 0.000 description 1
- OKLDUOSOWJLAEZ-XUWROFSHSA-N C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCCc1c2)c1ccc2Cl)OCCOC)[C@@H](C)S3(=O)=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCCc1c2)c1ccc2Cl)OCCOC)[C@@H](C)S3(=O)=O OKLDUOSOWJLAEZ-XUWROFSHSA-N 0.000 description 1
- DYPDQGQTBDWIRD-RRFCIEKPSA-N C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)[C@@H](C1CC1)S3(=O)=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)[C@@H](C1CC1)S3(=O)=O DYPDQGQTBDWIRD-RRFCIEKPSA-N 0.000 description 1
- DYPDQGQTBDWIRD-AMCLYCLISA-N C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)[C@H](C1CC1)S3(=O)=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)[C@H](C1CC1)S3(=O)=O DYPDQGQTBDWIRD-AMCLYCLISA-N 0.000 description 1
- KMEWCJKTMLQURO-FUNQAQBZSA-N C[C@@H](C/C=C/[C@@H]([C@H]1[C@H](CN(C2)c(cc(cc3)C(N)=O)c3OC[C@@]2(CCCc2c3)c2ccc3Cl)CC1)O)[C@@H](C1CCC1)S=O Chemical compound C[C@@H](C/C=C/[C@@H]([C@H]1[C@H](CN(C2)c(cc(cc3)C(N)=O)c3OC[C@@]2(CCCc2c3)c2ccc3Cl)CC1)O)[C@@H](C1CCC1)S=O KMEWCJKTMLQURO-FUNQAQBZSA-N 0.000 description 1
- PTOVDECAXIXIJX-YIQGEHEJSA-N C[C@@H](C/C=C/[C@H](C)[C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)CS3(=O)=O Chemical compound C[C@@H](C/C=C/[C@H](C)[C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)CS3(=O)=O PTOVDECAXIXIJX-YIQGEHEJSA-N 0.000 description 1
- TZXUKIKWIWXSCF-LVKMXRMZSA-N C[C@@H](CC/C=C/[C@@H]([C@H]1[C@H](CN(CCCC2)c3cc(C=O)ccc3OCc(cc3)c2cc3Cl)CC1)O)S(NC)(=O)=O Chemical compound C[C@@H](CC/C=C/[C@@H]([C@H]1[C@H](CN(CCCC2)c3cc(C=O)ccc3OCc(cc3)c2cc3Cl)CC1)O)S(NC)(=O)=O TZXUKIKWIWXSCF-LVKMXRMZSA-N 0.000 description 1
- FQGUIFDAZPUIDZ-FTNKSUMCSA-N C[C@@H](CC=C)C(CC1CCC1)S(N)(=O)=O Chemical compound C[C@@H](CC=C)C(CC1CCC1)S(N)(=O)=O FQGUIFDAZPUIDZ-FTNKSUMCSA-N 0.000 description 1
- OCSITWXGPHLSLB-NKWVEPMBSA-N C[C@@H](CC=C)[C@@H](C)S(N)(=O)=O Chemical compound C[C@@H](CC=C)[C@@H](C)S(N)(=O)=O OCSITWXGPHLSLB-NKWVEPMBSA-N 0.000 description 1
- FQGUIFDAZPUIDZ-GXSJLCMTSA-N C[C@@H](CC=C)[C@@H](CC1CCC1)S(N)(=O)=O Chemical compound C[C@@H](CC=C)[C@@H](CC1CCC1)S(N)(=O)=O FQGUIFDAZPUIDZ-GXSJLCMTSA-N 0.000 description 1
- SANDWQVPTHKCAU-NFSYPCPTSA-N C[C@H](C/C=C/C([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)[C@@H](C)S3(=O)=O Chemical compound C[C@H](C/C=C/C([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)C(N3)=O)c2OCc(cc2)c1cc2Cl)O)[C@@H](C)S3(=O)=O SANDWQVPTHKCAU-NFSYPCPTSA-N 0.000 description 1
- DNMICIWBCRNZAR-HBBYNOKHSA-N C[C@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(C(N2)O)cc3)c3OCc(cc3)c1cc3Cl)O)[C@H](C1CC1)S2(=O)=O Chemical compound C[C@H](C/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(C(N2)O)cc3)c3OCc(cc3)c1cc3Cl)O)[C@H](C1CC1)S2(=O)=O DNMICIWBCRNZAR-HBBYNOKHSA-N 0.000 description 1
- OTWJPNKFZAKNIH-HGKNVWHNSA-N C[C@H](C/C=C/[C@H](C)[C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCCc1c2)c1ccc2Cl)CS3(=O)=O Chemical compound C[C@H](C/C=C/[C@H](C)[C@H](CC1)[C@@H]1CN(C1)c(cc(cc2)C(N3)=O)c2OC[C@@]1(CCCc1c2)c1ccc2Cl)CS3(=O)=O OTWJPNKFZAKNIH-HGKNVWHNSA-N 0.000 description 1
- JGHJURDFEUADPG-AZMYOACGSA-N C[C@H](CC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)/C(/N3)=[O]/C)c2OCc(cc2)c1cc2Cl)O)S3(=O)=O Chemical compound C[C@H](CC/C=C/[C@@H]([C@H](CC1)[C@@H]1CN(CCCC1)c(cc(cc2)/C(/N3)=[O]/C)c2OCc(cc2)c1cc2Cl)O)S3(=O)=O JGHJURDFEUADPG-AZMYOACGSA-N 0.000 description 1
- TZMRTMQZSBAQNW-AZMYOACGSA-N C[C@H](CC/C=C/[C@@H]([C@H]1[C@H](CN(CCCC2)c3cc(C(N)=O)ccc3OCc(cc3)c2cc3Cl)CC1)OC)S Chemical compound C[C@H](CC/C=C/[C@@H]([C@H]1[C@H](CN(CCCC2)c3cc(C(N)=O)ccc3OCc(cc3)c2cc3Cl)CC1)OC)S TZMRTMQZSBAQNW-AZMYOACGSA-N 0.000 description 1
- KIGMAFLFLGALPM-KRZAECMESA-N C[C@H](CC/C=C/[C@H](C)[C@H](CC1)C1(C)CN(C1)c2cc(C(N3)=O)ccc2OC[C@@]11c2ccc(C)cc2CCC1)S3(=O)=O Chemical compound C[C@H](CC/C=C/[C@H](C)[C@H](CC1)C1(C)CN(C1)c2cc(C(N3)=O)ccc2OC[C@@]11c2ccc(C)cc2CCC1)S3(=O)=O KIGMAFLFLGALPM-KRZAECMESA-N 0.000 description 1
- TZVPYIOAZYVQGW-FQRUVTKNSA-N C[C@H](CC=C)[C@@H](CC1CC1)S(N(Cc(cc1)ccc1OC)Cc(cc1)ccc1OC)(=O)=O Chemical compound C[C@H](CC=C)[C@@H](CC1CC1)S(N(Cc(cc1)ccc1OC)Cc(cc1)ccc1OC)(=O)=O TZVPYIOAZYVQGW-FQRUVTKNSA-N 0.000 description 1
- OFOWSVAWNXCSIL-MRVPVSSYSA-N C[C@H](CCCc1c2)c1ccc2Cl Chemical compound C[C@H](CCCc1c2)c1ccc2Cl OFOWSVAWNXCSIL-MRVPVSSYSA-N 0.000 description 1
- TZCXTIQFQYDYDU-UHFFFAOYSA-N [NH-]C=[N+](c(cc1)cc(N(CC(CC2)C2C(C=CCCCS(=O)=O)O)CCCC2)c1OCc(cc1)c2cc1Cl)[O-] Chemical compound [NH-]C=[N+](c(cc1)cc(N(CC(CC2)C2C(C=CCCCS(=O)=O)O)CCCC2)c1OCc(cc1)c2cc1Cl)[O-] TZCXTIQFQYDYDU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043929P | 2014-08-29 | 2014-08-29 | |
| US62/043,929 | 2014-08-29 | ||
| PCT/US2015/047472 WO2016033486A1 (en) | 2014-08-29 | 2015-08-28 | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015308735A1 AU2015308735A1 (en) | 2017-03-23 |
| AU2015308735B2 true AU2015308735B2 (en) | 2019-03-14 |
Family
ID=54238507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015308735A Active AU2015308735B2 (en) | 2014-08-29 | 2015-08-28 | Compounds that inhibit Mcl-1 protein |
Country Status (41)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (en) * | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| EP4483875A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| AU2017300738A1 (en) | 2016-07-22 | 2019-02-07 | Les Laboratoires Servier | Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| WO2018237026A1 (en) | 2017-06-20 | 2018-12-27 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| TW201920193A (zh) * | 2017-08-15 | 2019-06-01 | 美商艾伯維有限公司 | 大環ｍｅｌ-１抑制劑以及使用方法 |
| CN111818917A (zh) * | 2017-08-15 | 2020-10-23 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
| ES3036998T3 (en) | 2017-08-18 | 2025-09-26 | Amgen Inc | Compounds that inhibit mcl-1 protein |
| MA50033A (fr) | 2017-08-29 | 2020-07-08 | Amgen Inc | Composés macrocycliques permettant d'inhiber la protéine mcl-1 |
| WO2019173181A1 (en) | 2018-03-05 | 2019-09-12 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere mcl-1 protein antagonists |
| DK3793565T3 (en) * | 2018-05-14 | 2022-03-07 | Gilead Sciences Inc | Mcl-1-inhibitorer |
| KR20210089662A (ko) * | 2018-11-09 | 2021-07-16 | 프렐루드 테라퓨틱스, 인코포레이티드 | 골수 세포 백혈병-1 (mcl-1) 단백질의 억제제로서 스피로-술폰아미드 유도체 |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| TWI745836B (zh) * | 2019-01-18 | 2021-11-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑製劑的大螺環醚 |
| CN114728076A (zh) | 2019-05-20 | 2022-07-08 | 诺华股份有限公司 | Mcl-1抑制剂抗体-药物缀合物及使用方法 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| KR20220024694A (ko) * | 2019-06-21 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | Mcl-1의 거대환식 억제제 |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| WO2021005043A1 (en) | 2019-07-09 | 2021-01-14 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
| EP3771469A1 (en) * | 2019-07-30 | 2021-02-03 | Amgen, Inc | Formulations and dosages for administering a compound that inhibits mcl1 protein |
| CN112479876B (zh) * | 2019-09-12 | 2023-07-21 | 苏州亚盛药业有限公司 | 氧氮杂环庚烷类螺环化合物、中间体及其制备方法 |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| CN115894606A (zh) | 2019-11-04 | 2023-04-04 | 锐新医药公司 | Ras抑制剂 |
| WO2021091967A1 (en) * | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TWI778443B (zh) * | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CA3159951A1 (en) * | 2019-11-26 | 2021-06-03 | Gilead Sciences, Inc. | Processes and intermediates for preparing mcl1 inhibitors |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| JP2023514364A (ja) * | 2020-02-21 | 2023-04-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状インドール誘導体 |
| JP2021161114A (ja) * | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Ｍｃｌ−１化合物のメチル化 |
| WO2021211922A1 (en) * | 2020-04-16 | 2021-10-21 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
| EP4143194A1 (en) | 2020-05-01 | 2023-03-08 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
| CN115515931B (zh) * | 2020-05-06 | 2024-10-18 | 安进公司 | 磺酰胺中间体的合成 |
| CA3181189A1 (en) * | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic alcohol intermediates |
| TWI867217B (zh) * | 2020-05-06 | 2024-12-21 | 美商安進公司 | 乙烯基環丁基中間體之合成 |
| CN118908912A (zh) * | 2020-05-06 | 2024-11-08 | 安进公司 | 乙烯基保护的醇中间体的合成 |
| TWI827924B (zh) * | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
| MX2022015813A (es) | 2020-06-10 | 2023-01-24 | Janssen Pharmaceutica Nv | 2-amino-3-fluoro-but-3-enamidas macrociclicas como inhibidores de mcl-1. |
| CN116249705A (zh) * | 2020-09-03 | 2023-06-09 | 安进公司 | 通过亲核芳族取代的二醇去对称化 |
| KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
| EP4247783A1 (en) * | 2020-11-19 | 2023-09-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
| KR20230138444A (ko) | 2020-11-24 | 2023-10-05 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| CA3202548A1 (en) * | 2020-11-25 | 2022-06-02 | Amgen Inc. | Enantioselective alkenylation of aldehydes |
| WO2022122667A1 (en) | 2020-12-07 | 2022-06-16 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| US20240083890A1 (en) | 2020-12-17 | 2024-03-14 | Janssen Pharmaceutica Nv | Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3215312A1 (en) | 2021-04-26 | 2022-11-03 | Frederik Jan Rita Rombouts | Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1 |
| CN118852330A (zh) | 2021-05-05 | 2024-10-29 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法 |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CA3234909A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| JP2024541979A (ja) | 2021-10-29 | 2024-11-13 | ギリアード サイエンシーズ， インコーポレイテッド | Ｃｄ７３化合物 |
| CA3237011A1 (en) | 2021-11-16 | 2023-05-25 | Soufyan JERHAOUI | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| KR20240125012A (ko) | 2021-12-22 | 2024-08-19 | 길리애드 사이언시즈, 인코포레이티드 | 이카로스 아연 핑거 패밀리 분해제 및 이의 용도 |
| CN118488946A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| DK4245756T3 (da) | 2022-03-17 | 2024-10-21 | Gilead Sciences Inc | Ikaros zinkfinger-familiens nedbrydere og anvendelse heraf |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| JP2025511331A (ja) | 2022-04-05 | 2025-04-15 | アムジエン・インコーポレーテツド | Ｍｃｉ－１アンタゴニストの非晶質及び結晶性形態 |
| EP4504737A1 (en) | 2022-04-05 | 2025-02-12 | Amgen Inc. | Salt forms and solvates of mci-1 antagonists |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Compounds modulate KRAS G12D |
| KR20250027285A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법 |
| CR20240570A (es) | 2022-07-01 | 2025-03-03 | Gilead Sciences Inc | Compuestos de cd73 |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| KR20250122479A (ko) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20240383922A1 (en) | 2023-04-11 | 2024-11-21 | Gilead Sciences, Inc. | KRAS Modulating Compounds |
| AU2024259556A1 (en) | 2023-04-21 | 2025-10-23 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250100998A1 (en) | 2023-07-26 | 2025-03-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4516807A1 (en) | 2023-08-28 | 2025-03-05 | Consorcio Centro de Investigación Biomédica en Red | Compositions for use in a method of providing improved hematopoietic stem cell engraftment |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013149124A1 (en) * | 2012-03-29 | 2013-10-03 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| JP5193861B2 (ja) * | 2005-07-07 | 2013-05-08 | アボット・ラボラトリーズ | アポトーシス促進剤 |
| US8445679B2 (en) | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
| EP2185562B1 (en) * | 2007-07-27 | 2015-12-02 | Janssen Pharmaceutica, N.V. | Pyrrolopyrimidines useful for the treatment of proliferative diseases |
| WO2011022312A1 (en) * | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Ether benzotriazole derivatives |
| WO2011044375A2 (en) * | 2009-10-08 | 2011-04-14 | Sanford-Burnham Medical Research Institute | Apogossypolone derivatives as anticancer agents |
| EP3138838A1 (en) | 2010-01-29 | 2017-03-08 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| US9486422B2 (en) | 2011-10-06 | 2016-11-08 | The Regents Of The University Of Michigan | Small molecule inhibitors of Mcl-1 and the uses of thereof |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| WO2017147410A1 (en) | 2016-02-25 | 2017-08-31 | Amgen Inc. | Compounds that inhibit mcl-1 protein |
-
2015
- 2015-08-27 JO JOP/2015/0208A patent/JO3474B1/ar active
- 2015-08-28 PE PE2017000362A patent/PE20170892A1/es unknown
- 2015-08-28 KR KR1020177008470A patent/KR102466351B1/ko active Active
- 2015-08-28 HR HRP20190053TT patent/HRP20190053T1/hr unknown
- 2015-08-28 SM SM20190048T patent/SMT201900048T1/it unknown
- 2015-08-28 TR TR2019/01312T patent/TR201901312T4/tr unknown
- 2015-08-28 JP JP2017511734A patent/JP6502479B2/ja active Active
- 2015-08-28 MX MX2017002656A patent/MX379155B/es unknown
- 2015-08-28 MY MYPI2017000299A patent/MY176235A/en unknown
- 2015-08-28 CA CA2959615A patent/CA2959615C/en active Active
- 2015-08-28 CR CR20170116A patent/CR20170116A/es unknown
- 2015-08-28 HU HUE15772048A patent/HUE041806T2/hu unknown
- 2015-08-28 LT LTEP15772048.3T patent/LT3186259T/lt unknown
- 2015-08-28 RS RS20190094A patent/RS58276B1/sr unknown
- 2015-08-28 SG SG11201701525WA patent/SG11201701525WA/en unknown
- 2015-08-28 CN CN201580054328.4A patent/CN107001387B/zh active Active
- 2015-08-28 EP EP18187957.8A patent/EP3424931B1/en active Active
- 2015-08-28 AU AU2015308735A patent/AU2015308735B2/en active Active
- 2015-08-28 BR BR112017004209-6A patent/BR112017004209B1/pt active IP Right Grant
- 2015-08-28 ES ES18187957T patent/ES2777478T3/es active Active
- 2015-08-28 DK DK15772048.3T patent/DK3186259T3/en active
- 2015-08-28 AP AP2017009827A patent/AP2017009827A0/en unknown
- 2015-08-28 PT PT15772048T patent/PT3186259T/pt unknown
- 2015-08-28 EP EP15772048.3A patent/EP3186259B1/en active Active
- 2015-08-28 PL PL15772048T patent/PL3186259T3/pl unknown
- 2015-08-28 WO PCT/US2015/047472 patent/WO2016033486A1/en not_active Ceased
- 2015-08-28 US US14/839,149 patent/US9562061B2/en active Active
- 2015-08-28 ES ES15772048T patent/ES2706309T3/es active Active
- 2015-08-28 SI SI201530586T patent/SI3186259T1/sl unknown
- 2015-08-28 TW TW104128490A patent/TWI676628B/zh active
- 2015-08-28 EA EA201790492A patent/EA031223B1/ru not_active IP Right Cessation
- 2015-08-28 UA UAA201702910A patent/UA118233C2/uk unknown
- 2015-08-28 MA MA40111A patent/MA40111B1/fr unknown
- 2015-08-28 TN TN2017000067A patent/TN2017000067A1/en unknown
- 2015-08-28 ME MEP-2019-12A patent/ME03313B/me unknown
- 2015-08-31 AR ARP150102791A patent/AR101729A1/es active IP Right Grant
- 2015-08-31 UY UY0001036285A patent/UY36285A/es active IP Right Grant
-
2016
- 2016-12-12 US US15/376,456 patent/US10100063B2/en active Active
-
2017
- 2017-02-27 CL CL2017000469A patent/CL2017000469A1/es unknown
- 2017-02-28 PH PH12017500367A patent/PH12017500367A1/en unknown
- 2017-02-28 IL IL250843A patent/IL250843B/en active IP Right Grant
- 2017-03-10 ZA ZA2017/01763A patent/ZA201701763B/en unknown
- 2017-03-28 CO CONC2017/0002998A patent/CO2017002998A2/es unknown
-
2018
- 2018-03-07 IL IL257942A patent/IL257942B/en active IP Right Grant
- 2018-05-02 ZA ZA2018/02865A patent/ZA201802865B/en unknown
- 2018-09-05 US US16/121,750 patent/US10836779B2/en active Active
- 2018-09-06 US US16/123,030 patent/US10494381B2/en active Active
-
2019
- 2019-01-28 CY CY20191100117T patent/CY1121195T1/el unknown
- 2019-09-13 US US16/569,927 patent/US11001598B2/en active Active
-
2020
- 2020-10-21 US US17/075,864 patent/US11685747B2/en active Active
-
2023
- 2023-05-08 US US18/313,703 patent/US12024529B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013149124A1 (en) * | 2012-03-29 | 2013-10-03 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12024529B2 (en) | Compounds that inhibit MCL-1 protein | |
| EP3601297B9 (en) | Compounds that inhibit mcl-1 protein | |
| US11274105B2 (en) | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists | |
| EP3668878A1 (en) | Compounds that inhibit mcl-1 protein | |
| NZ729768B2 (en) | Tetrahydronaphthalene derivatives that inhibit mcl-1 protein | |
| HK40020443B (en) | Compounds that inhibit mcl-1 protein | |
| HK40020443A (en) | Compounds that inhibit mcl-1 protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOUNDS THAT INHIBIT MCL-1 PROTEIN |
|
| FGA | Letters patent sealed or granted (standard patent) |